Literature DB >> 20708057

Effect of antidepressants on brain-derived neurotrophic factor (BDNF) release from platelets in the rats.

Kimihiko Watanabe1, Eri Hashimoto, Wataru Ukai, Takao Ishii, Toshihiro Yoshinaga, Takafumi Ono, Masaru Tateno, Ippei Watanabe, Tomohiro Shirasaka, Satoshi Saito, Toshikazu Saito.   

Abstract

Brain-derived neurotrophic factor (BDNF) belongs to the neurotrophin family, and enhances the growth and maintenance of several neuronal systems. In addition, BDNF may promote neurogenesis and protect against hippocampal volume loss in depressive disorders. Although first detected in brain, BDNF also exists in peripheral tissues and is mainly stored in platelets and circulates in blood. Recent reports indicate that serum BDNF levels in depressive patients are lower than in control subjects, and antidepressant treatment increases serum BDNF levels in responders. A single report suggests that decreased serum BDNF in major depression is related to mechanisms of platelet BDNF release; however, the mechanisms of changes in BDNF blood levels are still poorly understood. In the present study, we investigated the direct influence of antidepressants on BDNF release from platelets and their effects on serum levels. We used samples of washed platelets prepared from rat blood, and investigated the platelet BDNF release and serum BDNF concentration changes in response to adding antidepressants. We found that BDNF was dose-dependently released from platelets by direct treatment with various kinds of antidepressants in vitro, and serum BDNF concentration was also increased by intravenous antidepressant treatment. These results confirm that BDNF release from platelets is affected by antidepressants, which may relate to the circulating BDNF level change in peripheral blood. The response of BDNF release differs depending on the type and amount of antidepressants, making BDNF a serious candidate as a predictor of antidepressant treatment response.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20708057     DOI: 10.1016/j.pnpbp.2010.07.036

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  21 in total

1.  High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression.

Authors:  Thorsten Mikoteit; Johannes Beck; Anne Eckert; Ulrich Hemmeter; Serge Brand; Roland Bischof; Edith Holsboer-Trachsler; Alexandra Delini-Stula
Journal:  Psychopharmacology (Berl)       Date:  2014-02-23       Impact factor: 4.530

Review 2.  Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation?

Authors:  Montserrat Serra-Millàs
Journal:  World J Psychiatry       Date:  2016-03-22

Review 3.  Activity-regulated genes as mediators of neural circuit plasticity.

Authors:  Jennifer H Leslie; Elly Nedivi
Journal:  Prog Neurobiol       Date:  2011-05-12       Impact factor: 11.685

4.  Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations.

Authors:  Martin Le Nedelec; Paul Glue; Helen Winter; Chelsea Goulton; Lucy Broughton; Natalie Medlicott
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

5.  Brain-Derived Neurotrophic Factor in Alzheimer's Disease: Risk, Mechanisms, and Therapy.

Authors:  Jing-Hui Song; Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-10-30       Impact factor: 5.590

6.  Antidepressants and anti-inflammatory drugs differentially reduce the release of NGF and BDNF from rat platelets.

Authors:  T Hochstrasser; D Ehrlich; B Sperner-Unterweger; C Humpel
Journal:  Pharmacopsychiatry       Date:  2012-06-14       Impact factor: 5.788

7.  Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.

Authors:  Francis L Pazini; Mauricio P Cunha; Julia M Rosa; André R S Colla; Vicente Lieberknecht; Ágatha Oliveira; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2015-12-11       Impact factor: 5.590

8.  BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: results from a factorial, randomized, sham-controlled trial.

Authors:  André R Brunoni; Rodrigo Machado-Vieira; Carlos A Zarate; Erica L M Vieira; Marie-Anne Vanderhasselt; Michael A Nitsche; Leandro Valiengo; Isabela M Benseñor; Paulo A Lotufo; Wagner F Gattaz; Antonio L Teixeira
Journal:  Eur Neuropsychopharmacol       Date:  2014-03-27       Impact factor: 4.600

9.  The BDNF Val(66)Met polymorphism is associated with escitalopram response in depressed patients.

Authors:  Wissam El-Hage; Patrick Vourc'h; Philippe Gaillard; Julie Léger; Catherine Belzung; Yadira Ibarguen-Vargas; Christian R Andres; Vincent Camus
Journal:  Psychopharmacology (Berl)       Date:  2014-07-31       Impact factor: 4.530

10.  The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study.

Authors:  Maj Vinberg; Kamilla Miskowiak; Pernille Hoejman; Maria Pedersen; Lars Vedel Kessing
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.